MFDS Approves Domestic Clinical Trials for COVID-19 Vaccine Developed by US Innovio Inc.

[Asia Economy Reporter Choi Dae-yeol] The domestic clinical trial of the novel coronavirus disease (COVID-19) vaccine candidate (INO-4800) developed by the U.S. pharmaceutical company Inovio will commence.

According to the pharmaceutical industry on the 3rd, the International Vaccine Institute (IVI) received approval from the Ministry of Food and Drug Safety for phase 1 and phase 2 clinical trials of Inovio's COVID-19 vaccine candidate 'INO-4800' in South Korea.

This is the first time a COVID-19 vaccine clinical trial has been approved in South Korea. IVI received approval just 12 days after applying for the clinical trial with the Ministry of Food and Drug Safety.

The clinical trial is scheduled to be conducted this month at Seoul National University Hospital, targeting healthy adults.